膵・消化管NETの診断と治療レジメン

出版社： 医学と看護社
著者：
発行日： 2018-06-30
分野： 臨床医学：内科  >  肝/胆/膵
ISBN： 9784906829903
電子書籍版： 2018-06-30 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

集学的治療を必要とする神経内分泌腫瘍診療に必携のバイブル！

目次

  • I章 総論

    II章 病態別に見た治療戦略の立て方（診断～治療）
    　１. 転移を有する機能性膵NET
    　　a．インスリノーマ
    　　b．ガストリノーマ
    　　c．グルカゴノーマ、VIP産生腫瘍、ソマトスタチノーマ、カルチノイド症候群
    　２. 転移を有する非機能性膵NET
    　　a．NET G1/G2
    　　b．NET G3
    　c．NEC G3
    　３. 遺伝性疾患を背景としたNET治療
    　　a．MEN1
    　　b．VHL
    　４. 転移を有する消化管NET（症候性/無症候性含む）
    　　a．消化管NET
    　　b．消化管NEC
    　　c．消化管MiNEN

    III章 GEP-NET/NECに対する集学的治療（エビデンスの乏しい領域に対するエキスパートの考え方）
    　１. NACおよび補助化学療法について　その適応、エビデンス
    　２. 切除不能肝転移を有する場合の膵原発巣切除の意義について
    　３. 肝転移に対する外科介入の意義について
    　４. TAEはどのタイミングで行う？
    　５. 種々の薬物療法をどう使い分ける？
    　６. 非機能性NETに対するソマトスタチンアナログ併用の意義
    　７. PRRT　海外で行うには？

    IV章 薬剤のマネージメント
    　１. ソマトスタチンアナログ
    　２. エベロリムス
    　３. スニチニブ
    　４. ストレプトゾシン＋5-FU/S1
    　５. CAPTEM

    V章 診断のポイント
    　１. 膵NETに対するEUS-FNA
    　２. 膵神経内分泌腫瘍NET/NECの穿刺吸引生検検体を中心とした病理診断：WHO 2017分類も含め
    　３. ソマトスタチン受容体イメージング

    コラム
    　１．WHO2017改訂のポイント
    　２．遺伝子診断

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 総論

P.10 掲載の参考文献
1) Dasari A, Shen C, Halperin D, et al : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017 ; 3 : 1335-42
 
2) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2014 ; 50 : 58-64
 
3) Hijioka S, Hosoda W, Matsuo K, et al : Rb loss and KRAS mutation are predictors of the response to platinumbased chemotherapy in pancreatic neuroendocrine neoplasm with grade 3 : A Japanese multicenter pancreatic NEN-G3 study. Clin Cancer Res 2017 ; 23 : 4625-32
PubMed
4) Pezzilli R, Partelli S, Cannizzaro R, et al : Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs) : A systematic review. Adv Med Sci 2016 ; 61 : 147-53
 
P.13 掲載の参考文献
1) Lloyd RV, Osamura RY, Kloppel G, et al : WHO Classification of Tumours of Endocrine Organs. 4th ed, IARC, Lyon ; 2017 : 209-39
 
2) DeLellis R, Lloyd RV, Heitz P, et al : WHO Classification of Tumours. Pathology & Genetics. Tumours of Endocrine Organs. 3rd ed, IARC, Lyon ; 2004 : 175-208
 
3) Bosman FT, Carneiro F, Hruban RH, et al : WHO Classification of Tumours of the Digestive System. 4th ed, IARC, Lyon ; 2010
 

II章 病態別に見た治療戦略の立て方 ( 診断～治療 )

P.15 掲載の参考文献
1) Service FJ, McMahon MM, O'Brien PC, et al : Functioning insulinoma--incidence, recurrence, and long-term survival of patients : a 60-year study. Mayo Clin Proc 1991 ; 66 : 711-9
 
2) Minn AH, Kayton M, Lorang D, et al : Insulinomas and expression of an insulin splice variant. Lancet 2004 ; 363 : 363-7
 
3) Cryer PE, Axelrod L, Grossman AB, et al : Evaluation and management of adult hypoglycemic disorders : an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009 ; 94 : 709-28
 
4) Placzkowski KA, Vella A, Thompson GB, et al : Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009 ; 94 : 1069-73
 
5) Hirshberg B, Cochran C, Skarulis MC, et al : Malignant insulinoma : spectrum of unusual clinical features. Cancer 2005 ; 104 : 264-72
 
6) Gill GV, Rauf O, MacFarlane IA : Diazoxide treatment for insulinoma : a national UK survey. Postgrad Med J 1997 ; 73 : 640-1
PubMed
7) Jansson L, Kullin M, Karlsson FA, et al : K (ATP) channels and pancreatic islet blood flow in anesthetized rats : increased blood flow induced by potassium channel openers. Diabetes 2003 ; 52 : 2043-8
PubMed
8) Yao JC, Shah MH, Ito T, et al ; RAD001 in Advanced Neuroendocrine Tumors TiTR-SG : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
 
9) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
10) Dilz LM, Denecke T, Steffen IG, et al : Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015 ; 51 : 1253-62
 
11) Sward C, Johanson V, Nieveen van Dijkum E, et al : Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009 ; 96 : 517-21
 
12) Akyildiz HY, Mitchell J, Milas M, et al : Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases : long-term follow-up. Surgery 2010 ; 148 : 1288-93
 
13) Mayo SC, de Jong MC, Pulitano C, et al : Surgical management of hepatic neuroendocrine tumor metastasis : results from an international multi-institutional analysis. Ann Surg Oncol 2010 ; 17 : 3129-36
 
P.20 掲載の参考文献
1) Doi R, Komoto I, Nakamura Y, et al : Pancreatic Endocrine Tumor in Japan. Pancreas 2004 ; 28 : 247-52
 
2) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010 ; 45 : 234-43
 
3) Roy PK, Venzon DJ, Shojamanesh H, et al : Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000 ; 79 : 379-411
 
4) Jensen RT, Cadiot G, Brandi ML, et al : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms : functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012 ; 95 : 98-119
 
5) Imamura M, Komoto I, Ota S, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011 ; 17 : 1343-53
 
P.24 掲載の参考文献
1) Parker CM, Hanke CW, Madura JA, et al : Glucagonoma syndrome : case report and literature review. J Dermatol Surg Oncol 1984 ; 10 : 884-9
 
2) Soga J, Yakuwa Y : Glucagonomas/diabetico-dermatogenic syndrome (DDS) : a statistical evaluation of 407 reported cases. J Hepatobiliary Pancreat Surg1998 ; 5 : 312-9
 
3) Wermers RA, Fatourechi V, Wynne AG, et al : The glucagonoma syndrome. Clinical and pathologic features in 21 patients. Medicine (Baltimore) 1996 ; 75 : 53-63
 
4) Mullans EA, Cohen PR : Iatrogenic necrolytic migratory erythema : a case report and review of nonglucagonomaassociated necrolytic migratory erythema. J Am Acad Dermatol 1998 ; 38 : 866-73
 
5) Wermers RA, Fatourechi V, Kvols LK : Clinical spectrum of hyperglucagonemia associated with malignant neuroendocrine tumors. Mayo Clin Proc 1996 ; 71 : 1030-8
 
6) Donowitz M, Kokke FT, Saidi R : Evaluation of patients with chronic diarrhea. N Engl J Med 1995 ; 332 : 725-9
 
7) American Gastroenterological Association medical position statement : guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999 ; 116 : 1461-3
 
8) Kirkwood KS, Debas HT : Neuroendocrine tumors : Common presentations of uncommon diseases. Compr Ther 1995 ; 21 : 719-25
 
9) Angeletti S, Corleto VD, Schillaci O, et al : Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998 ; 42 : 792-4
 
P.29 掲載の参考文献
1) Hijioka M, Ito T, Igarashi H, et al : Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Sci 2014 ; 105 : 1464-71
 
2) Hasegawa T, Yamao K, Hijioka S, et al : Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014 ; 46 : 32-8
PubMed
3) Hijioka S, Hosoda W, Mizuno N, et al : Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol 2015 ; 50 : 564-72
 
4) Ito T, Jensen RT : Imaging in multiple endocrine neoplasia type 1 : recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol 2016 ; 3 : 53-66
 
5) Ito T, Hijioka S, Masui T, et al : Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 2016 Aug 18. [Epub ahead of print] DOI : 10.1007/s00535-016-1250-9
 
6) Ito T, Lee L, Jensen RT : Treatment of symptomatic neuroendocrine tumor syndromes : recent advances and controversies. Expert Opin Pharmacother 2016 Sep 16. [Epub ahead of print] DOI : 10.1080/14656566.2016.1236916
 
7) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010 ; 45 : 234-43
 
8) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64
 
9) Bosman FT, Carneiro F, Hruban RH, et al : WHO Classification of Tumours of the Digestive System, Vol 3, 4th edn. Lyon : IARC, 2010
 
10) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
11) Yachida S, Vakiani E, White CM, et al : Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012 ; 36 : 173-84
 
12) 五十嵐久人, 河邉顕, 伊藤鉄英 : 膵内分泌腫瘍の診断と内科的治療 インスリノーマ. 膵臓 2008 ; 23 : 676-84
 
13) 今村正之監修 : 膵・消化管神経内分泌腫瘍 (NET) 診断・治療・実践マニュアル, 総合医学社, 東京 ; 2011
 
14) Igarashi H, Ito T, Takayanagi R : The new concept of therapeutic strategy for neuroendocrine tumors : the important information from a case report of gastrinoma. Internal Med. 2010 ; 49 : 1839-40
 
15) Ito T, Jensen RT : Primary hepatic gastrinoma : an unusual case of zollinger-ellison syndrome. Gastroenterol Hepatol (NY) 2010 ; 6 : 57-9
 
16) Imamura M : Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J Gastroenterol 2010 ; 16 : 4519-25
 
17) Singh S, Law C, Chromogranin A : A sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012 ; 6 : 313-34
 
18) Modlin IM, Gustafsson BI, Moss SF, et al : Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Annals of Surgical Oncology 2010 ; 17 : 2427-43
 
19) Oberg K, Eriksson B : Endocrine tumours of the pancreas. Best Practice and Research : Clinical Gastroenterology 2005 ; 19 : 753-81
 
20) Malaguarnera M, Cristaldi E, Cammalleri L, et al : Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr 2009 ; 48 : 213-7
 
21) Pezzilli R, Partelli S, Cannizzaro R, et al : Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs) : A systematic review. Adv Med Sci 2016 ; 61 : 147-53
 
22) Scigliano S, Lebtahi R, Maire F, et al : Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases : a 15-year monocentric experience. Endocr Relat Cancer 2009 ; 16 : 977-90
 
23) Bodei L, Sundin A, Kidd M, et al : The status of neuroendocrine tumor imaging : from darkness to light? Neuroendocrinology 2015 ; 101 : 1-17
 
24) Kunz PL, Reidy-Lagunes D, Anthony LB, et al : Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 2013 ; 42 : 557-77
 
25) Eriksson B, Kloppel G, Krenning E, et al : Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. Neuroendocrinology 2008 ; 87 : 8-19
 
26) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 : 172-85
 
27) Arnold R, Chen YJ, Costa F, et al : ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors : follow-up and documentation. Neuroendocrinology 2009 ; 90 : 227-33
 
28) Christ E, Wild D, Ederer S, et al : Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas : a prospective multicentre imaging study. Lancet Diabetes Endocrinol 2013 ; 1 : 115-22
 
29) Xu Y, Pan D, Xu Q, et al : Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe 18F-FBEM-Cys39-exendin-4. J Cancer Res Clin Oncol 2014 ; 140 : 1479-88
 
30) Yao JC, Shah M, Ito T, et al : RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Eng J Med 2011 ; 364 : 514-23
 
31) Ito T, Okusaka T, Ikeda M, et al : Everolimus for advanced pancreatic neuroendocrine tumours : a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial. Jpn J Clin Oncol 2012 ; 42 : 903-11
PubMed
32) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Eng J Med 2011 ; 364 : 501-13
 
33) Ito T, Okusaka T, Nishida T, et al : Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013 ; 31 : 1265-74
 
34) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Eng J Med 1992 ; 326 : 519-23
PubMed
35) Aoki T, Kokudo N, Komoto I, et al : Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors : an analysis of a multi-center survey in Japan. J Gastroenterol 2015 ; 50 : 769-75
 
36) Lee L, Igarashi H, Fujimori N, et al : Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms : a single-center retrospective study. Jpn J Clin Oncol 2015 ; 45 : 1131-8
PubMed
37) 日本神経内分泌腫瘍研究会 (JNETS), 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : 膵・神経内分泌腫瘍 (NET) 診療ガイドライン, 金原出版, 東京 ; 2015
 
P.33 掲載の参考文献
1) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
2) Raj N, Valentino E, Capanu M, et al : Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology : Well Differentiated Versus Poorly Differentiated. Pancreas 2017 ; 46 : 296-301
 
3) Hijioka S, Hosoda W, Matsuo K, et al : Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3 : A Japanese Multicenter Pancreatic NEN-G3 Study. Clin Cancer Res 2017 ; 23 : 4625-32
PubMed
4) Catena L, Bajetta E, Milione M, et al : Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma : clinical and therapeutic future challenges. Target Oncol 2011 ; 6 : 65-8
 
5) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
6) Garcia-Carbonero R, Sorbye H, Baudin E, et al : ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016 ; 103 : 186-94
 
7) Fine RL, Gulati AP, Tsushima D, et al : Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.. J Clin Oncol 2014 ; 32 : 179
 
8) Haugvik SP, Janson ET, Osterlund P, et al : Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016 ; 23 : 1721-8
 
9) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 : 172-85
 
P.35 掲載の参考文献
1) Lloyd RV, Osamura RY, G.Kloppel G : WHO Classification of Tumours of Endocrine Organs, 4th Ed, 2017
 
2) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
3) Yamaguchi T, Machida N, Kasuga A : Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system. J Clin Oncol 2012 ; 30 (suppl 4) abstr 274
 
4) Garcia-Carbonero R, Sorbye H, Baudin E, et al : ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016 ; 103 : 186-94
 
P.41 掲載の参考文献
1) 小澤厚志, 山田正信 : 多発性内分泌腫瘍の病態生理と臨床像. 日本臨床 2011 ; 69 : 681-5
 
2) Thakker RV, Newey PJ, Walls GV, et al : Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012 ; 97 : 2990-3011
 
3) Sakurai A, Suzuki S, Kosugi S, et al : Multiple endocrine neoplasia type 1 in Japan : establishment and analysis of a multicentre database. Clin Endocrinol (Oxf) 2012 ; 76 : 533-9
 
4) Verges B, Boureille F, Goudet P, et al : Pituitary disease in MEN type 1 (MEN1) : data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002 ; 87 : 457-65
 
5) Chandrasekharappa SC, Guru SC, Manickam P, et al : Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997 ; 276 : 404-7
 
6) Huang J, Gurung B, Wan B, et al : The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 2012 ; 482 : 542-6
 
7) Agarwal SK, Guru SC, Heppner C, et al : Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999 ; 96 : 143-52
 
8) Karnik SK, Hughes CM, Gu X, et al : Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 2005 ; 102 : 14659-64
 
9) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010 ; 45 : 234-43
 
10) Sakurai A, Yamazaki M, Suzuki S, et al : Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1 : analysis of the database of the MEN Consortium of Japan. Endocr J 2012 ; 59 : 859-66
 
11) Imamura M, Komoto I, Ota S, et al : Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011 ; 17 : 1343-53
 
12) 多発性内分泌腫瘍症診療ガイドブック編集委員会編 : 多発性内分泌腫瘍症診療ガイドブック, 2013
 
13) 日本神経内分泌腫瘍研究会 (JNETS) 編 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン, 2015
 
14) Glascock MJ, Carty SE : Multiple endocrine neoplasia type 1 : fresh perspective on clinical features and penetrance. Surg Oncol 2002 ; 11 : 143-50
 
15) Goudet P, Murat A, Binquet C, et al : Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010 ; 34 : 249-55
 
16) Owens M, Ellard S, Vaidya B : Analysis of gross deletions in the MEN1 gene in patients with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2008 ; 68 : 350-4
 
17) Ozawa A, Agarwal SK, Mateo CM, et al : The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J Clin Endocrinol Metab 2007 ; 92 : 1948-51
 
18) Agarwal SK, Mateo CM, Marx SJ : Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009 ; 94 : 1826-34
 
19) 日本医学会ホームページ <http://jams.med.or.jp>
 
P.44 掲載の参考文献
1) Lonser ER, Glenn GM, Walther M, et al : von Hippel-Lindau disease. Lancet 2003 ; 361 : 2059-67
 
2) Latif F, Tory K, Gnarra J, et al : Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993 ; 260 : 1317-20
 
3) 五十嵐久人, 植田圭二郎, 立花雄一, 他 : 膵神経内分泌腫瘍と遺伝性疾患 (MEN1, von Hippel-Lindau病など). 胆と膵 2016 ; 37 : 899-904
 
4) 五十嵐久人, 立花雄一, 植田圭二郎, 他 : von Hippel-Lindau病. 肝胆膵 2016 ; 73 : 821-8
 
5) 執印太郎, 「フォン・ヒッペル・リンドウ病の病態調査と診断治療系確立の研究」班編 : フォン・ヒッペル・リンドウ (VHL) 病診療ガイドライン, 中外医学社, 東京 ; 2011
 
6) Igarashi H, Ito T, Nishimori I, et al : Pancreatic involvement in Japanese patients with von Hippel-Lindau disease : results of a nationwide survey. J Gastroenterol 2014 ; 49 : 511-6
 
7) Charlesworth M, Verbeke CS, Falk GA, et al : Pancreatic lesions in von Hippel-Lindau disease? Review and metasynthesis of the literature. J Gastrointest Surg 2012 ; 16 : 1422-8
 
8) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 ; 50 : 58-64
 
9) Park TY, Lee SK, Park JS, et al : Clinical features of pancreatic involvement in von-Hippel-Lindau disease : a retorospective study of 55 cases in a single center. Scan J Gastroenterol 2015 ; 50 : 360-7
 
10) Keutgen XM, Hammel P, Choyke PL, et al : Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol 2016 ; 13 : 537-49
 
11) Blansfield JA, Choyke L, Morita SY, et al : Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery 2007 ; 142 : 814-8
 
12) Miki M, Kawabe K, Igarashi H, et al : An advanced well-differentiated pancreatic neuroendocrine carcinoma (NET-G3) associated with von Hippel-Lindau disease. Intern Med, in press
 
13) 五十嵐久人, 伊藤鉄英, 肱岡真之, 他 : von Hippel-Lindau (VHL) 病に伴う膵NET. 胆と膵 2014 ; 35 : 669-70
 
14) Benitez Velazco A, Pacheco Capote C, Latre Romero JM : Ectopic Cushing's syndrome caused by a functioning pancreatic neuroendocrine tumour in a patient with von Hippel-Lindau disease. Rev Esp Med Nucl 2008 ; 27 : 29-33
 
15) Hatipoglu E, Kepicoglu H, Rusen E, et al : Von Hippel Lindau disease with metastatic pancreatic neuroendocrine tumor causing ectopic Cushing's syndrome. Neuro Endocrinol Lett 2013 ; 34 : 9-13
 
16) Sala Hernandez A, Montalva Oron EM, Pareja Ibars E, et al : Management of pancreatic gastrinoma associated with Von Hippel-Lindau disease : a case report. Rev Esp Enferm Dig 2017 ; 109 : 154-7
 
17) van Asselt SJ, Brouwers AH, van Dullemen HM, et al : Potential value of EUS in pancreatic surveillance of VHL patients. Eur J Endocrinol 2016 ; 174 : 611-20
PubMed
18) Libutti SK, Choyke PL, Bartlett DL, et al : Pancreatic neuroendocrine tumors associated with von Hipplel Lindau disease : diagnostic and management recommendations. Surgery 1998 ; 124 : 1153-9
 
19) Corcos O, Couvelard A, Giraud S, et al : Endocrine pancreatic tumors in von Hippel-Lindau disease : clinical, histological, and genetic features. Pancreas 2008 ; 37 : 85-93
 
20) de Mestier L, Gaujoux S, Cros J, et al : Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg 2015 ; 262 : 384-8
 
21) Ito T, Sasano H, Tanaka M, et al : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010 ; 45 : 234-43
 
22) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン 2015年, 第1版, 金原出版, 東京 ; 2015
 
23) Ito T, Honma Y, Hijioka S, et al : Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 2017 ; 35 : 499-508
PubMed
24) Kobayashi A, Takahashi M, Imai H, et al : Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease. Intern Med 2016 ; 55 : 629-34
 
25) Babinska A, Studniarek M, Swiatkowska-Stodulska R, et al : Sunitinib treatment for multifocal renal cell carcinoma (RCC) and pancreatic neuroendocrine tumor (NET) in patient with Von Hippel-Lindau disease. Case Report. Neuro Endocrinol Lett 2015 ; 36 : 517-20
 
26) Wang W, Jiang CY, Wang HW, et al : Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome. J Clin Gastroenterol 2015 ; 49 : 89-90
 
27) Ali T, Kandil D, Piperdi B, et al : Long-term disease control with sunitinib in a patient with metastatic pancreatic neuroendocrine tumor (NET) associated with von Hippel-Lindau syndrome (VHL). Pancreas 2012 ; 41 : 492-3
 
28) Roma A, Maruzzo M, Basso U, et al : First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease : clinical outcome and patterns of radiological response. Fam Cancer 2015 ; 14 : 309-16
 
29) Knickelbein JE, Jacobs-El N, Wong WT, et al : Systemic sunitinib malate treatment for advanced juxtapapillary retinal hemangioblastomas associated with von Hippel-Lindau disease. Ophthalmol Retina 2017 ; 1 : 181-7
 
P.49 掲載の参考文献
1) Yao JC, Hassan M, Phan A, et al : One Hundred Years After "Carcinoid" : Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J Clin Oncol 2018 : 26 : 3063-72
 
2) Dasari A, Shen C, Halperin D, et al : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017 : 3 : 1335-42
 
3) Ito T, Igarashi H, Nakamura K, et al : Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan : a nationwide survey analysis. J Gastroenterol 2015 : 50 : 58-64
 
4) Pavel M, Baudin E, Couvelard A, et al : ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastasses from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinol 2012 : 95 : 157-76
 
5) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Brohchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinol 2016 : 103 : 172-85
 
6) NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine and Adrenal Tumors Version1.2018 : NCCN Guidelines for Treatment of Cancer by Site. https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
 
7) Sarmiento JM, Heywood G, Rubin J, et al : Surgical Treatment of Neuroendocrine Metastases to the Liver : A Plea for Resection to Increase Survival. J Am Coll Surg 2003 : 197 : 29-37
 
8) Mayo SC, Herman JM, Cosgrove D, et al : Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis : Role of Liver-Directed and Systemic Therapies. J Am Coll Surg 2013 : 216 : 123-34
 
9) Sarmiento JM, Que FG : Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin North Am 2003 : 12 : 231-42
 
10) Maxwell JE, Sherman SK, O'Dorisio TM, et al : Liver-Directed Surgery of Neuroendocrine Metastases : What is the Optimal Strategy? Surgery 2016 : 159 : 320-35
 
11) Rinke A, Muller HH, Schade-Brittinger C, et al : PROMID Study Group : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 : 27 : 4656-63
 
12) Yao JC, Fazio N, Singh S, Buzzoni R, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 : 387 : 968-77
 
13) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
14) Ito T, Honma Y, Hijioka S, et al : Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors. Invest New Drugs 2017 : 35 : 499-508
PubMed
15) 日本神経内分泌腫瘍研究会編 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン,金原出版, 東京 ; 2015
 
P.54 掲載の参考文献
1) Garcia-Carbonero R, Sorbye H, Baudin E, et al : ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 2016 ; 103 : 186-94
 
2) Yamaguchi T, Machida N, Morizane C, et al : Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 2014 ; 105 : 1176-81
 
3) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : The NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
4) Dasari A, Mehta K, Byers LA, et al : Comparative Study of Lung and Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas : A SEER Database Analysis of 162,983 Cases. Cancer 2017 Dec 6. doi : 10.1002/cncr.31124. [Epub ahead of print]
 
5) Walter T, Tougeron D, Baudin E, et al : Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas : Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017 Jul ; 79 : 158-65. doi : 10.1016/j.ejca.2017.04.009. Epub 2017 May 11
 
6) 千野修, 幕内博康, 小澤壯治, 他 : 食道神経内分泌細胞癌の内視鏡診断-形態学的・病理組織学的特徴と診療における問題点. 胃と腸 2017 ; 52 : 402-11
 
7) 中平博子, 上堂文也, 荒尾真道, 他 : 胃内分泌細胞癌の内視鏡所見の特徴-胃内分泌腫瘍との比較から. 胃と腸 2017 ; 52 : 413-22
 
8) 島田麻里, 海崎泰治, 平沼知加志, 他 : 大腸内分泌細胞癌の臨床病理学的検討. 胃と腸 2017 ; 52 : 423-9
 
9) 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン. URL : http://jnets.umin.jp/pdf/guideline001_1s.pdf
 
10) NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors. version 3. 2017. URL : https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf
 
11) Noda K, Nishiwaki Y, Kawahara M, et al : IRINOTECAN PLUS CISPLATIN COMPARED WITH ETOPOSIDE PLUS CISPLATIN FOR EXTENSIVE SMALL-CELL LUNG CANCER. N Engl J Med 2002 ; 346 : 85-91
 
12) Moertel CG, Kvols LK, O'Connell MJ, et al : Treatment of neuroendocrine carcinomas with combined etoposideand cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991 ; 68 : 227-32
 
13) Mitry E, Baudin E, Ducreux M, et al : Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999 ; 81 : 1351-5
PubMed
14) Patta A, Fakih M : First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET) : review of 8 cases. Anticancer Res 2011 ; 31 : 975-8
PubMed
15) Ramella Munhoz R, de Mendonca Rego JF, de Celis Ferrari AR, et al : Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare Tumors 2013 ; 5 : e39
 
16) Okita NT, Kato K, Takahari D, et al : Neuroendocrine tumors of the stomach : chemotherapy with cisplatin plus irinotecan is effective for gastric poorly differentiated neuroendocrine carcinoma. Gastric Cancer 2011 ; 14 : 161-5
PubMed
17) Nakano K, Takahashi S, Yuasa T, et al : Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol 2012 ; 42 : 697-703
 
18) Okuma HS, Iwasa S, Shoji H, et al : Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. Anticancer Res 2014 ; 34 : 5037-41
 
19) Lu Z, Li J, Lu M, et al : Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas. Med Oncol 2013 ; 30 : 664
 
20) Hadoux J, Malka D, Planchard D, et al : Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer 2015 ; 22 : 289-98
 
21) Bajetta E, Catena L, Procopio G, et al : Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007 ; 59 : 637-42
 
22) Ferrarotto R, Testa L, Riechelmann RP, et al : Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors. Rare Tumors 2013 ; 5 : e35
PubMed
23) Hentic O, Hammel P, Couvelard A, et al : FOLFIRI regimen : an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012 ; 19 : 751-7
 
24) Araki T, Takashima A, Hamaguchi T, et al : Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract. Anticancer Drugs 2016 Sep ; 27 (8) : 794-9. doi : 10.1097/CAD.0000000000000393
 
25) Olsen IH, Sorensen JB, Federspiel B, et al : Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Scientific World Journal 2012 ; 2012 : 170496
PubMed
26) Welin S, Sorbye H, Sebjornsen S, et al : Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011 ; 117 : 4617-22
PubMed
27) Walter T, Malka D, Hentic O, et al : Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma : The PRODIGE 41-BEVANEC randomized phase II study. Dig Liver Dis 2017 Dec 6. pii : S1590-8658 (17) 31316-6. doi : 10.1016/j.dld.2017.11.020. [Epub ahead of print]
 
P.58 掲載の参考文献
1) 1) Lloyd RV, Osamura RY, Kloppel G, et al : Neoplasms of the neuroendocrine pancreas. WHO Classification of Tumours of the Endocrine Organs, ed 4. Lyon, IARC Press, 2017, 210-39
 
2) Volante M, Rindi G, Papotti M : The grey zone between pure (neuro) endocrine and non- (neuro) endocrine tumours : a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch 2006 ; 449 : 499-506
 
3) La Rosa S, Marando A, Sessa F, et al : Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract : An Update. Cancers 2012 ; 4 : 11-30
PubMed
4) de Mestier L, Cros J, Neuzillet C, et al : Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology 2017 ; 105 : 412-25
 
5) Medley L, Morel AN, Farrugia D, et al : Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011 ; 104 : 1067-70
 
6) Faure M, Niccoli P, Autret A, et al : Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017 ; 6 : 44-48
 
7) Spada F, Antonuzzo L, Marconcini R, et al : Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors : Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology 2016 ; 103 : 806-14
 
8) Mitry E, Walter T, Baudin E, et al : Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) -A phase II non-randomised trial. Eur J Cancer 2014 ; 50 : 3107-15
 
9) Kunz PL, Balise RR, Fehrenbacher L, et al : Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors : An Analysis of 2 Phase II Trials. Pancreas 2016 ; 45 : 1394-400
 

III章 GEP - NET / NECに対する集学的治療 ( エビデンスの乏しい領域に対するエキスパートの考え方 )

P.62 掲載の参考文献
1) Sorbye H, Westre B, Horn A : Curative surgery after neoadjuvant chemotherapy in metastatic poorly differentiated neuroendocrine carcinoma. Eur J Surg Oncol 2007 ; 33 : 1209-10
PubMed
2) Lessing Y, Ben-Haim M, Lahat G, et al : Surgery after neoadjuvant chemotherapy for locally advanced extrapulmonary poorly differentiated neuroendocrine cancer. Am Surg 2011 ; 77 : 1102-4
 
3) Sorbye H, Strosberg J, Baudin E, et al : Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014 ; 120 : 2814-23
 
4) Haugvik SP, Janson ET, Osterlund P, et al : Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016 ; 23 : 1721-8
 
5) Prakash L, Bhosale P, Cloyd J, et al : Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2016 ; 21 : 155-63
 
6) Lee J, Choi J, Choi C, et al : Role of radiotherapy for pancreatobiliary neuroendocrine tumors. Radiat Oncol J 2013 ; 31 : 125-30
 
7) Claringbold PG, Brayshaw PA, Price RA, et al : Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2011 ; 38 : 302-11
 
8) Kaemmerer D, Prasad V, Daffner W, et al : Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009 ; 15 : 5867-70
 
9) Stoeltzing O, Loss M, Huber E, et al : Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 2010 ; 395 : 185-92
 
10) Barber TW, Hofman MS, Thomson BN, et al : The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. Eur J Surg Oncol 2012 ; 38 : 64-71
 
11) Ezziddin S, Lauschke H, Schaefers M, et al : Neoadjuvant downsizing by internal radiation : a case for preoperative peptide receptor radionuclide therapy in patients with pancreatic neuroendocrine tumors. Clin Nucl Med 2012 ; 37 : 102-4
 
12) Pavel M, Baudin E, Couvelard A, et al : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012 ; 95 : 157-76
 
13) Le Treut YP, Gregoire E, Klempnauer J, et al : Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection : a 213-case European liver transplant registry study. Ann Surg 2013 ; 257 : 807-15
 
14) Mazzaferro V, Sposito C, Coppa J, et al : The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. Am J Transplant 2016 ; 16 : 2892-902
 
P.64 掲載の参考文献
1) Kulke MH, Anthony LB, Bushnell DL, et al : NANETS treatment guidelines : well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010 ; 39 : 735-52
 
2) Givi B, Pommier SJ, Thompson AK, et al : Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006 ; 14 : 891-7
 
3) Frilling A, Modlin IM, Kidd M, et al : Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014 ; 15 : e8-21
 
4) Nguyen SQ, Angel LP, Divino CM, et al : Surgery in malignant pancreatic neuroendocrine tumors. J Surg Oncol 2007 ; 96 : 397-403
 
5) Solorzano CC, Lee JE, Pisters PW, et al : Nonfunctioning islet cell carcinoma of the pancreas : survival results in a contemporary series of 163 patients. Surgery 2001 ; 130 : 1078-85
 
6) Bettini R, Mantovani W, Boninsegna L, et al : Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Dig Liver Dis 2009 ; 41 : 49-55
 
7) Capurso G, Bettini R, Rinzivillo M, et al. Role of resection of the primary pancreatic Nnuroendocrine tumour only in patients with unresectable metastatic liver disease : A systematic review. Neuroendocrinology 2011 ; 93 : 223-9
 
8) Partelli S, Cirocchi R, Rancoita PMV, et al : A systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. HPB (Oxford), in press, doi : 10.1016/j.hpb.2017.10.014
 
9) Huttner FJ, Schneider L, Tarantino I, et al : Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas : a population-based, propensity score-matched survival analysis. Langenbecks Arch Surg 2015 ; 400 : 715-23
 
10) Keutgen XM, Nilubol N, Glanville J, et al : Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors.Surgery 2016 ; 159 : 311-8
PubMed
11) Citterio D, Pusceddu S, Facciorusso A, et al : Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. Euro J Surg Oncol 2017 ; 43 : 380-7
 
12) Bertani E, Fazio N, Radice D : Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. Eur J Surg Oncol 2017 ; 43 : 372-9
 
13) 青木琢, 國土典宏 : GEP-NET に対する外科治療. 日消誌 2014 ; 111 : 2272-9
 
14) Hasegawa T, Yamao K, Hijioka S, et al : Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors. Endoscopy 2014 ; 46 : 32-8
PubMed
15) Otsubo T, Kobayashi S, Sano K, et al : Safety-related outcomes of the Japanese Society of Hepato-Biliary-Pancreatic Surgery board certification system for expert surgeons. J Hepatobiliary Pancreat Sci 2017 ; 24 : 252-61
 
P.68 掲載の参考文献
1) Yao JC, Hassan M, Phan A, et al : One hundred years after "carcinoid" : epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008 ; 26 : 3063-72
 
2) Modlin IM, Lye KD, Kidd M : A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003 ; 97 : 934-59
 
3) Lloyd RV, Osamura RY, Kloppel G, et al (eds) : WHO classification of tumours of endocrine organs. Fourth edition. IARC, Lyon, 2017
 
4) Pavel M, O'Toole D, Costa F, et al : ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016 ; 103 : 172-85
 
5) Frilling A, Modlin IM, Kidd M, et al : Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014 ; 15 : e8-e21
 
6) Musunuru S, Chen H, Raipal S, et al : Metastatic neuroendocrine hepatic tumors : resection improves survival. Arch Surg 2006 ; 141 : 1000-4
 
7) Mayo SC, de Jong MC, Pulitano C, et al : Surgical management of hepatic neuroendocrine tumor metastasis : results from an international multi-institutional analysis. Ann Surg Oncol 2010 ; 17 : 3129-36
 
8) Bagante F, Spolverato G, Merath K, et al : Neuroendocrine liver metastasis : the chance to be cured after liver surgery. J Surg Oncol 2017 ; 115 : 687-95
PubMed
9) Sploverato G, Bagante F, Aldrighetti L, et al : Neuroendocrine liver metastasis : prognostic implications of primary tumor site on patients undergoing curative intent liver surgery. J Gastrointest Surg 2017 ; 21 : 2039-47
 
10) Sarmiento JM, Heywood G, Robin J, et al : Surgical treatment of neuroendocrine metastases to the liver : a plea for resection to increase survival. J Am Coll Surg 2003 ; 197 : 29-37
 
11) Morgan RE, Pommier SJ, Pommier RF : Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery 2018 ; 163 : 218-25
 
12) Maxwell JE, Sherman SK, O'Dorisio TM, et al : Liver-directed surgery of neuroendocrine metastases : what is the optimal strategy? Surgery 2016 ; 159 : 320-33
 
13) Yao JC, Pavel M, Lombard-Bohas C, et al : Everolimus for the treatment of advanced pancreatic neuroendocrine tumors : overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 Study. J Clin Oncol 2016 ; 34 : 3906-13
 
14) Faivre S, Niccoli P, Castellano D, et al : Sunitinib in pancreatic neuroendocrine tumors : updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017 ; 28 : 339-43
 
15) Lam VW, Spiro C, Laurence JM, et al : A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012 ; 19 : 1292-301
 
P.72 掲載の参考文献
1) Gupta S, Johnson MM, Murthy R, et al : Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors : variables affecting response rates and survival. Cancer 2005 ; 104 : 1590-602
 
2) Maire F, Lombard-Bohas C, O'Toole D, et al : Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors : a prospective randomized study. Neuroendocrinology 2012 ; 96 : 294-300
 
3) Marrache F, Vullierme MP, Roy C, et al : Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 2007 ; 96 : 49-55
 
4) Kim YH, Ajani JA, Carrasco CH, et al : Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. Cancer Invest 1999 ; 17 : 474-8
PubMed
5) Do Minh D, Chapiro J, Gorodetski B, et al : Intra-arterial therapy of neuroendocrine tumour liver metastases : comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol 2017 ; 27 : 4995-5005
 
6) Guiu B, Deschamps F, Aho S, et al : Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma : lipiodol vs. drug-eluting beads. J Hepatol 2012 ; 56 : 609-17
PubMed
7) Joskin J, de Baere T, Auperin A, et al : Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Intervent Radiol 2015 ; 38 : 372-80
 
8) Bhagat N, Reyes DK, Lin M, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases : high incidence of biliary injury. Cardiovasc Intervent Radiol 2013 ; 36 : 449-59
PubMed
9) Makary MS, Kapke J, Yildiz V, et al : Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol 2016 ; 27 : 1298-304
 
10) Sahu S, Schernthaner R, Ardon R, et al : Imaging Biomarkers of Tumor Response in Neuroendocrine Liver Metastases Treated with Transarterial Chemoembolization : Can Enhancing Tumor Burden of the Whole Liver Help Predict Patient Survival? Radiology 2017 ; 283 : 883-94
 
11) Kitano M, Davidson GW, Shirley LA, et al. Transarterial Chemoembolization for Metastatic Neuroendocrine Tumors With Massive Hepatic Tumor Burden : Is the Benefit Worth the Risk? Ann Surg Oncol 2016 ; 23 : 4008-15
 
12) Eriksson BK, Larsson EG, Skogseid BM, et al : Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998 ; 83 : 2293-301
 
13) Ho AS, Picus J, Darcy MD, et al : Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. AJR Am J Roentgenol 2007 ; 188 : 1201-7
 
14) Pavel M, Baudin E, Couvelard A, et al : ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012 ; 95 : 157-76
 
15) Roche A, Girish BV, de Baere T, et al : Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003 ; 13 : 136-40
 
16) de Baere T, Deschamps F, Tselikas L, et al : GEP-NETS update : Interventional radiology : role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 2015 ; 172 : R151-66
 
P.77 掲載の参考文献
1) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
2) Yao JC, Pavel M, Lombard-Bohas C, et al : Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors : Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study. J Clin Oncol 2016 ; 34 : 3906-13
 
3) Raymond E, Dahan L, Raoul J-L, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
4) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 : 519-23
PubMed
5) Yao J, Phan AT : Optimising Therapeutic Options for Patients with advanced Pancreatic Neuroendocrine Tumours. Eur Oncol Haematol 2012 ; 8 : 217-23
 
6) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
7) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
8) Sun W, Lipsitz S, Catalano P, et al : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005 ; 23 : 4897-904
PubMed
9) Ikeda M, Okuyama H, Takahashi H, et al : Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. Hepatobiliary Pancreat Sci 2015 ; 22 : 623-7
 
10) Morizane C, Machida N, Honma Y, et al : Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system : A Japan Clinical Oncology Group study (JCOG1213). J Clin Oncol 2015 ; 33 (suppl ; abstr TPS4143)
 
P.81 掲載の参考文献
1) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
2) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
3) Yao JC, Lombard-Bohas C, Baudin E, et al : Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy : a phase II trial. J Clin Oncol 2010 ; 28 : 69-76
 
4) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
5) Kulke MH, Ruszniewski P, Van Cutsem E, et al : A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors : COOPERATE-2 trial. Ann Oncol 2017 ; 28 : 1309-15
 
6) Bajetta E, Catena L, Fazio N, et al. Everolimus in combination with octreotide long-acting repeatable in a firstline setting for patients with neuroendocrine tumors : an ITMO group study. Cancer 2014 ; 120 : 2457-63
 
7) Capdevila J, Sevilla I, Alonso V, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice : a retrospective cross-sectional analysis. BMC Cancer 2015 ; 15 : 495
PubMed
8) Brizzi MP, Berruti A, Ferrero A, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer 2009 ; 9 : 388
PubMed
9) Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors : the XELBEVOCT study. BMC Cancer 2014 ; 14 : 184
PubMed
10) Phan AT, Halperin DM, Chan JA, et al : Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours : a multicentre, single-group, phase 2 study. Lancet Oncol 2015 ; 16 : 695-703
 
11) Jalbert JJ, Casciano R, Tao B, et al : Treatment patterns among patients with metastatic GEP-NET treated at a tertiary referral center. ASCO-GI abstract 397 2017
 
12) Benson Iii AB, Broder MS, Cai B, et al : Real-world treatment patterns of gastrointestinal neuroendocrine tumors : A claims database analysis. World J Gastroenterol 2017 ; 23 : 6128-36
 
P.87 掲載の参考文献
1) Krenning EP, Bakker WH, Breeman WA, et al : Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1989 ; 1 : 242-4
 
2) Krenning EP, Bakker WH, Kooij PPM, et al : Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in Man : Metabolism, Dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992 ; 33 : 652-8
 
3) Otte A, Jermann E, Behe M, et al : DOTATOC : a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997 ; 24 : 792-5
 
4) Otte A, Mueller-Brand J, Dellas S, et al : Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998 ; 35 : 417-8
 
5) Kam BL, Teunissen JJ, Krenning EP, et al : Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2012 ; 39 Suppl 1 : S103-12
 
6) Strosberg JR, EI-Haddad G, Wolin E, et al : Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 2017 ; 376 : 125-35
 
7) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 2016 ; 103 : 172-85
 
8) Sansovini S, Nanni O, Bodei L, et al : Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013 ; 40 : 881-8
 
9) Ezziddin S, Attassi M, Yong-Hing CJ, et al : Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Luoctreotate. J Nucl Med 2014 ; 55 : 183-90
 
10) Brabander T, van der Zwan WA, Teunissen JJM, et al : Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res 2017 ; 23 : 4617-24
PubMed
11) Mariniello A, Bodei L, Tinelli C, et al : Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 2016 ; 43 : 441-52
 
12) Sabet A, Haug AR, Eiden C, et al : Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotatae in metastatic pulmonary neuroendocrine tumors : a dual-centre analysis. Am J Nuck Med Mol Imaging 2017 ; 7 : 74-83
 
13) Kwekkeboom DJ, Kam BL, van Essen M, et al : Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010 ; 17 : R53-73
 
14) Imhof A, Brunner P, Marincek N, et al : Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA] -TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011 ; 29 : 2416-23
PubMed

IV章 薬剤のマネージメント

P.91 掲載の参考文献
1) Rinke A, Muller HH, Schade-Brittinger C, et al : Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors : a report from the PROMID Study Group. J Clin Oncol 2009 ; 27 : 4656-63
 
2) Caplin ME, Pavel M, Cwikla JB, et al : Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014 ; 371 : 224-33
PubMed
3) Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ, et al : Octreotide. N Engl J Med 1996 ; 334 : 246-54
 
4) Oberg K : Cancer : antitumor effects of octreotide LAR, a somatostatin analog. Nat Rev Endocrinol 2010 ; 6 : 188-9
 
5) Pavel M, O'Toole D, Costa F, et al : ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016 ; 103 (2) : 172-85
 
6) Vinik AI, Wolin EM, Liyanage N, et al : EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT) : A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Endocr Pract 2016 ; 22 : 1068-80
 
7) Bruns C, Lewis I, Briner U, et al : SOM230 : a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002 ; 146 : 707-16
 
8) Gadelha MR, Bronstein MD, Brue T, et al : Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA) : a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014 ; 2 : 875-84
 
9) Wolin EM, Jarzab B, Eriksson B, et al : Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. Drug Des Devel Ther 2015 ; 9 : 5075-86
 
10) Biermasz NR : New medical therapies on the horizon : oral octreotide. Pituitary 2017 ; 20 : 149-53
 
P.95 掲載の参考文献
1) アフィニトール錠 神経内分泌腫瘍 適正使用ガイド ノバルティスファーマ株式会社
 
2) Shimobayashi M, Hall MN : Making new contacts : the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol 2014 ; 15 : 155-62
 
3) Laplante M, Sabatini DM : mTOR signaling in growth control and disease. Cell 2012 ; 149 : 274-93
 
4) Yao JC, Shah MH, Ito T, et al : Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 514-23
PubMed
5) Yao JC, Fazio N, Singh S, et al : Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) : a randomised, placebo-controlled, phase 3 study. Lancet 2016 ; 387 : 968-77
 
6) Davies M, Saxena A, Kingswood JC : Management of everolimus-associated adverse events in patients with tuberous sclerosis complex : a practical guide. Orphanet J Rare Dis 2017 ; 12 : 35
PubMed
7) Champion L, Stern M, Israel-Biet D, et al : Brief communication : sirolimus-associated pneumonitis : 24 cases in renal transplant recipients. Ann Intern Med 2006 ; 144 : 505-9
 
8) Ohnishi H, Yokoyama A, Kondo K, et al : Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002 ; 165 : 378-81
PubMed
9) Sonis S, Andreotta PW, Lyng G : On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS) -studies using an organotypic model of the oral mucosa. Oral Dis 2017 ; 23 : 347-52
 
10) Vigarios E, Epstein JB, Sibaud V : Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer 2017 ; 25 : 1713-39
 
11) Martins F, de Oliveira MA, Wang Q, et al : A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 2013 ; 49 : 293-8
 
12) Boers-Doets CB, Lalla RV. The mIAS scale : a scale to measure mTOR inhibitor-associated stomatitis. Support Care Cancer 2013 ; 21 (S1) : S140
 
13) Rugo HS, Seneviratne L, Beck JT, et al : Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH) : a singlearm, phase 2 trial. Lancet Oncol 2017 ; 18 : 654-62
 
14) Spring L, Bardia A : SWISH-ing steroids : new standard of care to prevent everolimus-induced oral mucositis? Lancet Oncol 2017 ; 18 : 564-65
 
15) Tsukamoto T, Shinohara N, Tsuchiya N, et al : Phase III trial of everolimus in metastatic renal cell carcinoma : subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol 2011 ; 41 : 17-24
PubMed
16) Rugo HS, Hortobagyi GN, Yao J, et al : Meta-analysis of stomatitis in clinical studies of everolimus : incidence and relationship with efficacy. Ann Oncol 2016 ; 27 : 519-25
 
17) Deppenweiler M, Falkowski S, Saint-Marcoux F,et al : Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res 2017 ; 121 : 138-44
 
18) 格口渉, 鈴木豊典, 藤田光平, 他 : 分子標的薬であるエベロリムスの関与が疑われた抜歯1か月後に生じた後出血の1例. 北海道歯学雑誌 2014 ; 35 : 42-7
 
19) Acharya GK, Hita AG, Yeung SJ, et al : Diabetic Ketoacidosis and Acute Pancreatitis : Serious Adverse Effects of Everolimus. Ann Emerg Med 2017 ; 69 : 666-7
 
20) Kim K, Jeong DW, Lee YH, et al : Everolimus-Induced Systemic Serositis After Simultaneous Liver and Kidney Transplantation : A Case Report. In : Transplantation proceedings. Elsevier, 2017 : 181-4
 
21) Fuhrer DK, Kobayashi M, Jiang H : Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes Obes Metab 2001 ; 3 : 393-402
 
22) Subramaniam S, Zell JA, Kunz PL : Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw 2013 ; 11 : 5-9
 
23) Dann SG, Selvaraj A, Thomas G : mTOR Complex1-S6K1 signaling : at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007 ; 13 : 252-9
 
24) Zoncu R, Efeyan A, Sabatini DM : mTOR : from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011 ; 12 : 21-35
 
25) Kwon G, Marshall CA, Liu H, et al : Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels : effects on cell cycle progression in rodent islets. J Biol Chem 2006 ; 281 : 3261-7
 
26) 北田宗弘, 古家大祐 : 栄養センシングと細胞機能の制御. 化学と生物 2013, 51 : 294-301
 
27) Lamming DW, Ye L, Katajisto P, et al : Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012 ; 335 : 1638-43
 
28) 柴田昌紀, 後藤景介, 林哲太郎, 他 : 転移性腎細胞癌に対するエベロリムス投与後に急性腎不全を来たした1例. 西日本泌尿器科 2013 ; 75 : 383-90
 
29) LEE CYS, Lee KL, Hirata KY, et al : Medication-Related Osteonecrosis of the Jaw with the mTOR Inhibitor Everolimus in a Patient with Estrogen-Receptor Positive Breast Cancer : A Case Report. Int J Oral Dent Health 2016 ; 2 : 033
 
P.101 掲載の参考文献
1) Raymond E, Dahan L, Raoul JL, et al : Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011 ; 364 : 501-13
 
2) Ito T, Okusaka T, Nishida T et al. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013 ; 31 : 1265-74
 
3) Faivre S, Niccoli P, Castellano D, et al : Sunitinib in pancreatic neuroendocrine tumors : updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 2017 ; 28 : 339-43
 
4) Raymond E, Kulke MH, Qin S, et al : The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. J Clin Oncol 2017 ; 35 : 380
 
5) Komatsu Y, Ohki E, Ueno N, et al : Safety, efficacy and prognostic analyses of sunitinib in the post-marketing surveillance study of Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 2015 ; 45 : 1016-22
PubMed
6) Baldazzi V, Tassi R, Lapini A, et al : The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients : a prospective single-center study. Urol Oncol 2012 ; 30 : 704-10
 
7) Rini BI, Cohen DP, Lu DR, et al : Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011 ; 103 : 763-73
 
8) Martins D, Spada F, Lambrescu I, et al : Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors. Target Oncol 2017 ; 12 : 611-22
 
P.106 掲載の参考文献
1) 池田公史, 今岡大, 奥山浩之, 他 : 本邦の膵神経内分泌腫瘍におけるストレプトゾシン療法の現状と展望. 胆と膵 2016 ; 37 : 905-10
Medical*Online
2) ノーベルファーマ株式会社. ザノサー(R) 適正使用ガイド. 2014年11月
 
3) Zhao FQ, Keating AF : Functional properties and genomics of glucose transporters. Curr Genomics 2007 ; 8 : 113-28
 
4) Schnedl WJ, Ferber S, Johnson J, et al : STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994 ; 43 : 1326-33
 
5) 肱岡範, 渋谷仁, 奥野のぞみ, 他 : pNETに対するストレプトゾシンの使い方について教えてください. 膵・胆道癌 FRONTIER 2017 ; 6 : 33-7
 
6) Moertel CG, Hanley JA : Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979 ; 2 : 327-34
 
7) Moertel CG, Johnson LA : Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980 ; 303 : 1189-94
 
8) Engstrom PF, Lavin PT, Moertel CG, et al : Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984 ; 2 : 1255-9
 
9) Eriksson B, Skoqseid B, Lundqvist G, et al : Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990 ; 65 : 1883-90
 
10) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 : 519-23
PubMed
11) Rivera E, Ajani JA : Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998 ; 21 : 36-8
 
12) Kouvaraki MA, Ajani JA, Hoff P, et al : Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004 ; 22 : 4762-71
 
13) Sun W, Lipsitz S, Catalano P, et al : Eastern Cooperative Oncology G : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005 ; 23 : 4897-904
 
14) Dahan L, Bonnetain F, Rougier P, et al : Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors : FNCLCC-FFCD 9710. Endocr Relat Cancer 2009 ; 16 : 1351-61
 
15) Turner NC, Strauss SJ, Sarker D, et al : Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer 2010 ; 102 : 1106-12
 
16) Meyer T, Qian W, Caplin ME, et al : Capecitabine and streptozocin +/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eur J Cancer 2014 ; 50 : 902-11
 
17) Naidoo J, O'Toole D, MJ Kennedy, et al : A single institution experience of streptozocin/fluorouracil combination chemotherapy : a case series. Ir J Med Sci 2012 ; 181 : 211-4
 
18) Ducreux M, Dahan L, Smith D, et al : Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) --a phase II non-randomised trial. Eur J Cancer 2014 ; 50 : 3098-106
 
19) Dilz LM, Denecke T, Steffen IG, et al : Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer 2015 ; 51 : 1253-62
 
20) Krug S, Boch M, Daniel H, et al : Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms-Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015 ; 10 : e0143822
PubMed
21) Aoki T, Kokudo N, Komoto I, et al : Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors : an analysis of a multi-center survey in Japan. J Gastroenterol 2015 ; 50 : 769-75
 
22) Clewemar Antonodimitrakis P, Sundin A, Wassberg C, et al : Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors : Efficacy, Prognostic Factors and Toxicity. Neuroendocrinology 2016 ; 103 : 345-53
 
23) Prakash L, Bhosale P, Cloyd J, et al : Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2017 ; 21 : 155-63
 
24) Krug S, Gress TM, Michl P, et al : The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors. Digestion 2017 ; 96 : 67-75
 
25) Krug S, Boch M, Rexin P, et al : Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors. Anticancer Res 2017 ; 37 : 2491-500
 
26) SEQTOR trial. ClinicalTrials gov ; NCT02246127
 
27) 渋谷仁, 肱岡範, 奥坂拓志, 他 : 進行膵神経内分泌腫瘍に対するstreptozocin療法の現状-国内17施設多施設共同研究-. 第5回日本神経内分泌腫瘍研究会学術集会 2017
 
28) 独立行政法人医薬品医療機器総合機構 : 独立行政法人医薬品医療機器総合機構ホームページ ストレプトゾシン審査報告書 2014 : 34-5 (http://www.pmda.go.jp/drugs/2014/P201400139/620095000_22600AMX01315_A100_2.pdf#search=%27%E3%82%B6%E3%83%8E%E3%82%B5%E3%83%BC+%E5%AF%A9%E6%9F%BB%E5%A0%B1%E5%91%8A%E6%9B%B8%27)
 
29) Hesketh PJ, Kris MG, Basch E, et al : Antiemetics : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2017 ; 35 : 3240-61
 
30) 薬剤性腎障害の診療ガイドライン作成委員会 : 薬剤性腎障害診療ガイドライン. 日腎会誌 2016 ; 58 : 477-555
 
P.111 掲載の参考文献
1) Moertel CG, Lefkopoulo M, Lipsitz S, et al : Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992 ; 326 : 519-23
PubMed
2) Sun W, Lipsitz S, Catalano P, et al ; Eastern Cooperative Oncology Group : Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors : Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005 ; 23 : 4897-904
PubMed
3) Fine RL, Gulati AP, Tsushima D, et al : Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol 2014 ; 32 (supple 3) : abstr 179
 
4) Fine RL, Gulati AP, Krantz BA, et al : Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers : The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013 ; 71 : 663-70
 
5) Cives M, Ghayouri M, Morse B, et al : Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 2016 ; 23 : 759-67
 

V章 診断のポイント

P.115 掲載の参考文献
1) 河本泉, 今村正之 : 膵消化管神経内分泌腫瘍の診断. 日消誌 2014 ; 111 : 2263-71
 
2) 花田敬士, 飯星知博, 平野巨通, 他 : 膵内分泌腫瘍の画像診断. 肝胆膵画像 2010 ; 12 : 438-48
 
3) 日本神経内分泌腫瘍研究会 (JNETS) 膵・消化管神経内分泌腫瘍診療ガイドライン作成委員会編 : 膵・消化管神経内分泌腫瘍 (NET) 診療ガイドライン, 金原出版, 東京 ; 2015
 
4) WHO Classification of Tumours of Endocrine Organs. Eds : Lloyd RV, et al : 4th Edition, 2017 IAPC Press, Lyon France
 
5) Pais SA, Al-Haddad M, Mohamadnejad M, et al : EUS for pancreatic neuroendocrine tumors : a-single center, 11-year experience. Gastroinetst Endosc 2010 ; 71 : 1185-93
 
6) Larghi A, Capurso G, Carnuccio A, et al : Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine needle tissue acquisition : a prospective study. Gastrointest Endosc 2012 ; 76 : 570-7
PubMed
7) Hijioka S, Hara K, Mizuno N, et al : Diagnostic performance and factors influencing the accuracy of EUS-FNA of pancreatic neuroendocrine neoplasms. J Gastroenterol 2016 ; 51 : 923-30
 
8) 花田敬士, 清水晃典, 丸山紘嗣, 他 : EUS-FNA私はこうする. 胆と膵 2017 ; 38 : 951-7
 
P.119 掲載の参考文献
1) Bosman FT, Camerio F, Hurban RH, et al : Pathology and Genetics Tumor of the Digestive system (World Health Organization Classification of Tumors) Lyon, IARC Press, 2010
 
2) Sorbye H, Welin S, Langer SW, et al : Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3) : the NORDIC NEC study. Ann Oncol 2013 ; 24 : 152-60
 
3) Lloyd R, Osamura RY, Kloppel G, et al (eds) : WHO Classification of Tumours of Endocrine Organs, 4th edition, IARC Press, Lyon, 2017
 
4) Basturk O, Yang Z, Tang LH, et al : The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015 ; 39 : 683-90
 
P.123 掲載の参考文献
1) Johnbeck CB, Knigge U, Kjar A : PET tracers for somatostatin receptor imaging of neuroendocrine tumors : current status and review of the literature. Future Oncol 2014 ; 10 : 2259-77
 
2) Bombardieri E, Ambrosini V, Aktolun C, et al : 111In-pentetreotide scintigraphy : procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010 ; 37 : 1441-8
 
3) Bozkurt MF, Virgolini I, Balogova S, et al : Guideline for PET/CT imaging of neuroendocrine neoplasms with (68) Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18) F-DOPA. Eur J Nucl Med Mol Imaging 2017 ; 44 : 1588-1601
 
4) Al-Ibraheem A, Bundschuh RA, Notni J, et al : Focal uptake of 68Ga-DOTATOC in the pancreas : pathological or physiological correlate in patients with neuroendocrine tumours? Eur J Nucl Med Mol Imaging 2011 ; 38 : 2005-13
PubMed
5) Buchmann I, Henze M, Engelbrecht S, et al : Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007 ; 34 : 1617-26
 
6) Gabriel M, Decristoforo C, Kendler D, et al : 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors : comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007 ; 48 : 508-18
 
7) Van Binnebeek S, Vanbilloen B, Baete K, et al : Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT : A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Eur Radiol 2016 ; 26 : 900-9
PubMed
8) Srirajaskanthan R, Kayani I, Quigley AM, et al : The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010 ; 51 : 875-82
PubMed
9) Treglia G, Castaldi P, Rindi G, et al : Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours : a meta-analysis. Endocrine 2012 ; 42 : 80-7
 
10) Geijer H, Breimer LH : Somatostatin receptor PET/CT in neuroendocrine tumours : update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013 ; 40 : 1770-80
 
11) Kubota K, Okasaki M, Minamimoto R, et al : Lesion-based analysis of (18) F-FDG uptake and (111) In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med 2014 ; 28 : 1004-10
PubMed
12) Strosberg J, El-Haddad G, Wolin E, et al : Phase 3 Trial of (177) Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med 2017 ; 376 : 125-35
PubMed
P.126 掲載の参考文献
1) Jiao Y, Shi C, Edil BH, et al : DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011 ; 331 : 1199-203
 
2) Raj N, Soumerai T, Valentino E, et al : Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs) : A study using MSK-IMPACT. J Clin Oncol 2016 ; 34 (suppl 4S) ; abstr 246
 
3) Scarpa A, Chang DK, Nones K, et al : Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 2017 ; 543 : 65-71
 
4) Singhi AD, Liu TC, Roncaioli JL, et al : Alterative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine tumors. Clin Cancer Res 2016 ; 23 : 600-9
 
5) Yachida S, Vakiani E, White CM, et al : Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 2012 ; 36 : 173-84
 
6) Bergsland EK, Roy R, Stephens P, et al : Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. J Clin Oncol 2016 ; 34 (suppl) ; abstr 4020
 
7) Hijioka S, Hosoda W, Matsuo K, et al : Rb loss and KRAS mutation are predictors of the response to platinum-based chemotherapy in pancreatic neuroendocrine neoplasm with grade 3 : A Japanese multicenter pancreatic NEN-G3 Study. Clin Cancer Res 2017 ; 23 : 4625-32
PubMed
8) Tang LH, Basturk O, Sue JJ, et al : A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am J Surg Pathol 2016 ; 40 : 1192-202
 
9) Ohmoto A, Rokutan H, Yachida S : Pancreatic neuroendocrine neoplasms : Basic biology, current treatment strategies and prospects for the future. Int J Mol Sci 2017 ; 18. pii : E143
 
10) Francis JM, Kiezun A, Ramos AH, et al : Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 2013 ; 45 : 1483-6
 

書評

最近チェックした商品履歴

Loading...